Divi's Laboratories closed FY26 with a strong quarter, reporting a net profit of ₹751 crore for Q4—a 13.4% jump from the year-ago period. This comfortably beat the CNBC-TV18 poll estimate of ₹713 crore. The outperformance wasn't driven by topline fireworks alone; revenue grew 9.5% year-on-year to ₹2,831 crore, slightly missing the street's expectation of ₹2,859 crore. Instead, the profit beat came down to a potent mix of favorable non-operating factors and disciplined expense management.
The star of the show was undoubtedly foreign exchange gains. The company booked a forex gain of ₹90 crore in Q4, a massive nine-fold increase from the ₹10 crore recorded in the same quarter last year. This one-time boost provided a direct lift to the bottom line, cushioning the impact of the revenue miss. Beyond this windfall, operational efficiency played a crucial role. Total expenses for the quarter stood at ₹2,023 crore. While this represents an increase, it grew at a measured pace relative to the revenue expansion. Key cost components remained well-contained: material costs consumed about 42% of revenue, while finance costs were negligible at just ₹6 crore. This tight control over the cost structure allowed the company to convert its revenue growth into profit growth more effectively than analysts had anticipated. AnnualReports
However, the quality of earnings showed some strain when looking at operating metrics. EBITDA margin declined to 33% in Q4 FY26, down from 34.3% in the prior year, and missed the CNBC-TV18 estimate of 34.2%. This 130 basis point compression highlights the operational challenges lurking beneath the headline profit growth. The primary culprits were well-known industry headwinds: elevated freight costs and rising raw material prices. Management has previously noted significant logistics disruptions, including vessel rerouting around the Cape of Good Hope, which extended shipping times and inflated freight costs to key markets like the US and Europe. These pressures, coupled with persistent pricing competition in the generic API segment, meant that costs rose faster than sales, leading to negative operating leverage. EBITDA grew only 5.4% year-on-year, significantly lagging the 9.5% revenue growth, which directly eroded the margin profile. Transcripts +1
The revenue shortfall of about ₹28 crore versus estimates, while minor, points to specific demand and supply dynamics. Management characterized the volume environment as "stable" rather than explosive, suggesting the company maintained market share without capturing significant incremental business. In the generic API business, which makes up nearly half the mix, intense competition limited pricing power. Any attempt to raise prices likely met resistance, forcing the company to prioritize volume maintenance over price increases. On the positive side, the higher-margin custom synthesis segment maintained strong momentum with an active project pipeline, and the nutraceutical business delivered robust 21% growth for the full year. However, the project-based nature of custom synthesis can introduce quarterly variability, and the timing of customer orders or inventory adjustments may have caused the slight revenue miss. Transcripts
Despite these margin pressures and the revenue dip, the board's decision to recommend a final dividend of ₹30 per share sends a powerful signal of confidence. This payout, representing a 1,500% dividend on the face value of ₹2, is maintained at the same level as the previous year. The commitment to shareholder returns is particularly noteworthy because FY26 was a peak investment year.
The fact that management chose to distribute approximately ₹797 crore to shareholders while simultaneously executing a massive expansion program speaks volumes about its financial discipline and cash generation capabilities.
Underpinning this dividend confidence is exceptional cash flow quality.
This cash conversion ratio of 1.07x indicates high-quality earnings where profits are genuinely converting into cash. The company sits on a net cash position of around ₹3,414 crore with zero financial leverage, providing ample liquidity to weather the near-term storm of freight and raw material inflation.
Looking ahead, the narrative for Divi's Laboratories is one of resilience and strategic positioning.
Its investments in complex areas like peptide synthesis and continuous flow chemistry are designed to capture higher-value opportunities. While the immediate horizon involves navigating freight cost pressures and raw material volatility, the strong exit rate in Q4, with the quarter recording the highest-ever revenue and profit, provides a solid foundation for FY27. The dividend announcement serves as a reassuring anchor for investors, signaling that despite the quarterly margin fluctuations, the company's long-term cash-generating engine remains robust and its balance sheet is built to sustain growth while rewarding shareholders. Transcripts
